Unicycive Therapeutics Inc. (UNCY)
NASDAQ (CM) NASDAQ (CM) Primary 
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts
Unicycive Therapeutics, Inc. (NASDAQ: UNCY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokers
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
I initiate Unicycive Therapeutics with a "Buy" rating, driven by the FDA's acceptance of its OLC NDA resubmission and a defined PDUFA date. OLC targets hyperphosphatemia in CKD dialysis patients, offering competitive advantages like lower pill burden, smaller size, and swallowable tablets. The prior FDA rejection was solely due to third-party manufacturing issues, not clinical data, increasing confidence in potential approval.
